Microsens Biotechnologies, London Bioscience Innovation Centre, 2 Royal College Street London, NW1 0NH
Tel. +44 (0)20 76912147, Fax. +44 (0)20 76912036, Email info@microsens.co.uk
An introduction to the Seprion ligand range
The misfolding of proteins and their subsequent aggregation in the brain is thought to be the cause of a group of related ‘Protein Aggregation Diseases’ including Parkinson’s, Alzheimer’s, Huntington’s and the Transmissible Spongiform Encephalopathies such as BSE, scrapie, vCJD and CWD.
For diagnosis, detection and research studies it is very difficult to differentiate
the abnormal aggregated form of the proteins from the normal unaggregated form. To
address this problem, Microsens has developed polymeric ligands (the ‘Seprion’ range)
which only binds to the abnormal aggregated form of the protein. The Seprion ligands
have been shown to bind abnormal prion, β-
The Seprion ligands have been used extensively in commercial BSE screening and in research applications such as the screening of tonsils for vCJD or in mouse models of various Protein Aggregation Diseases.
The Seprion ligands are supplied coated onto magnetic beads or onto ELISA plates which gives the researcher the flexibility of separation and assay format.
For more information. Please select a link on the left.
